Repligen Corporation $RGEN Shares Sold by KBC Group NV

KBC Group NV cut its stake in Repligen Corporation (NASDAQ:RGEN) by 40.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,522 shares of the biotechnology company’s stock after selling 1,022 shares during the quarter. KBC Group NV’s holdings in Repligen were worth $189,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of RGEN. Price T Rowe Associates Inc. MD increased its holdings in shares of Repligen by 6.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company’s stock valued at $962,711,000 after purchasing an additional 430,039 shares in the last quarter. Geneva Capital Management LLC grew its position in Repligen by 239.6% during the second quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock valued at $60,639,000 after buying an additional 343,991 shares during the period. Nuveen LLC purchased a new position in Repligen in the first quarter valued at $35,536,000. T. Rowe Price Investment Management Inc. raised its position in shares of Repligen by 64.0% in the first quarter. T. Rowe Price Investment Management Inc. now owns 260,848 shares of the biotechnology company’s stock worth $33,191,000 after acquiring an additional 101,791 shares during the period. Finally, Alyeska Investment Group L.P. boosted its stake in shares of Repligen by 24.0% during the 1st quarter. Alyeska Investment Group L.P. now owns 460,237 shares of the biotechnology company’s stock worth $58,561,000 after acquiring an additional 89,057 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Activity

In other Repligen news, Director Anthony Hunt sold 25,000 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $156.88, for a total value of $3,922,000.00. Following the completion of the sale, the director owned 100,743 shares in the company, valued at approximately $15,804,561.84. This represents a 19.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO James Bylund sold 2,191 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total transaction of $331,301.11. Following the completion of the transaction, the chief operating officer directly owned 21,520 shares in the company, valued at $3,254,039.20. This trade represents a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 49,382 shares of company stock worth $7,676,802. Insiders own 1.20% of the company’s stock.

Repligen Stock Up 1.3%

Shares of RGEN opened at $155.08 on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. Repligen Corporation has a one year low of $102.96 and a one year high of $182.52. The stock has a market capitalization of $8.73 billion, a price-to-earnings ratio of 7,757.88, a PEG ratio of 3.32 and a beta of 1.15. The stock has a 50 day moving average price of $142.99 and a 200 day moving average price of $129.99.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. Repligen had a return on equity of 4.70% and a net margin of 0.25%.The company had revenue of $188.81 million for the quarter, compared to analyst estimates of $181.23 million. During the same quarter last year, the firm posted $0.43 EPS. The firm’s revenue for the quarter was up 21.9% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Equities research analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RGEN has been the subject of several recent analyst reports. Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Jefferies Financial Group set a $160.00 price objective on Repligen and gave the company a “hold” rating in a research report on Tuesday, October 28th. Hsbc Global Res raised Repligen to a “strong-buy” rating in a research note on Wednesday, October 1st. HSBC assumed coverage on shares of Repligen in a research note on Wednesday, October 1st. They issued a “buy” rating and a $150.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $180.00 price objective on shares of Repligen in a research report on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.85.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.